Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.51 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429998 | 0.94 | PTGS1 (0.50) | PTGS1PTGS2MAPK14SLC34A1CSNK1A1 | |
| SCHEMBL21711325 | 0.74 | PTGS1 (0.49) | PTGS1PTGS2MAPK14CSNK1A1RPS6KA3 | |
| SCHEMBL5331845 | 0.73 | PTGS1 (1.00) | PTGS1PTGS2MAPK14CSNK1A1RPS6KA3 | |
| SCHEMBL21711385 | 0.73 | IKBKB (0.58) | MAPK14SLC34A1CSNK1A1RPS6KA3DAPK3 | |
| SCHEMBL20075417 | 0.73 | MAPK1 (0.69) | MAPK14SLC34A1CSNK1A1RPS6KA3DAPK3 | |
| SCHEMBL20074699 | 0.70 | PTGS1 (0.44) | PTGS1PTGS2SLC34A1KMT2AADORA2A | |
| SCHEMBL6132080 | 0.69 | MAPK1 (0.80) | MAPK14CSNK1A1RPS6KA3DAPK3PRKD3 | |
| SCHEMBL20074615 | 0.69 | MAPK14 (0.53) | MAPK14SLC34A1CSNK1A1RPS6KA3DAPK3 | |
| SCHEMBL6132067 | 0.69 | MAPK1 (0.80) | MAPK14CSNK1A1RPS6KA3DAPK3PRKD3 | |
| SCHEMBL20074664 | 0.69 | MAPK14 (0.53) | MAPK14CSNK1A1RPS6KA3DAPK3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| EP-3526212-B1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-12-22 | — | — | EP | disclosed |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| CN-110191884-A | Substituted 6- (1H-pyrazol-1-yl) pyrimidine-4-amine derivatives and uses thereof | 拜耳公司 | 2019-08-30 | — | — | CN | disclosed |
| WO-2018069222-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208400-B2 | Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof | REN, ATP6V1B1, GLS | PTGS1 332/4885PTGS2 641/4885MAPK14 3191/4885 |
| US-20200055842-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | PTGS1 332/4885PTGS2 641/4885MAPK14 3191/4885 |
| US-20230065629-A1 | SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | REN, ATP6V1B1, GLS | PTGS1 332/4885PTGS2 641/4885MAPK14 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.